Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)?

Ítems similars

• Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance
  per: Villadolid, Jeryl, et al.
  Publicat: (2015)
• Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
  per: Wang, Yuli, et al.
  Publicat: (2016)
• Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
  per: O’Kane, G.M., et al.
  Publicat: (2018)
• Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor
  per: Sakai, Kazuko, et al.
  Publicat: (2013)
• Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
  per: Lee, Sang Hoon, et al.
  Publicat: (2020)